You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
德琪醫藥(06996.HK):ATG-101澳洲一期臨牀試驗申請獲批
阿思達克 07-22 11:07
德琪醫藥(06996.HK)公佈,旗下創新藥ATG-101用於治療轉移性或晚期實體瘤及B細胞非霍奇金淋巴瘤的一期臨牀試驗申請,近日已獲得澳洲Bellberry人類研究倫理委員會批準,爲當地首款進入臨牀的PD-L1/4-1BB雙抗產品。

德琪醫藥創始人、董事長兼首席執行官梅建明表示,雙特異性抗體與聯用傳統單抗相比,製作成本低、週期短,是一類極具臨牀應用前景的藥物。目前已觀察到ATG-101在體內體外均有抗腫瘤活性,期望在臨牀中得到驗證,將加快這款藥物的臨牀進程,預計今年會在中美兩地遞交ATG-101的臨牀試驗申請。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account